DEF 14A: Forte Biosciences Sets Date for 2025 Annual Meeting, Outlines Key Proposals

Forte Biosciences announces its 2025 Annual Meeting of Stockholders to be held virtually on May 29, 2025, featuring proposals for director elections and ratification of the company's independent auditor.

Summary

• Forte Biosciences will hold its 2025 Annual Meeting of Stockholders on May 29, 2025, at 9:00 a.m. Eastern Time, conducted virtually.
• Stockholders will vote on the election of Richard Vincent, Shiv Kapoor, and David Gryska as Class II directors, each serving until the 2028 annual meeting.
• The meeting will also include a vote to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of KPMG LLP's appointment.
• The record date for determining stockholders eligible to vote is April 30, 2025.
• As of the record date, there were 6,583,382 shares of Common Stock outstanding.
• Proxy materials were first sent to stockholders on or about April 30, 2025.
• The Board held six meetings in 2024, with directors attending at least 75% of Board and committee meetings.
• The annual cash retainer for each Eligible Director was $42,500 in 2024.
• Each continuing Eligible Director will receive, on the date of each annual meeting of our stockholders held after January 1, 2026, an annual award of stock options to purchase 31,000 shares of our Common Stock.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing necessary information for stockholders. The outlook is stable, with no major positive or negative indicators.

Positives

• The company is adhering to corporate governance best practices by seeking stockholder ratification of the independent auditor.
• The Board is actively engaged, with directors demonstrating strong attendance at Board and committee meetings.
• The company provides clear information on how stockholders can participate in the annual meeting and vote their shares.
• The company has a formal, written policy regarding related person transactions.

Negatives

• Barbara Finck, M.D. is not considered an independent director because of the consulting fees provided her as our acting Senior Medical Clinician.
• Paul A. Wagner, Ph.D. is not considered an independent director because of his position as our president and chief executive officer.

Risks

• Failure to elect the nominated directors could disrupt the company's strategic direction.
• If stockholders do not ratify the appointment of KPMG LLP, the audit committee may reconsider the appointment.
• The company faces inherent business risks, including strategic, financial, legal, and operational risks.
• The company's success depends on its ability to manage these risks effectively.

Future Outlook

The company is focused on conducting the business outlined in the proxy statement at the upcoming Annual Meeting and continuing to operate under the guidance of its Board of Directors.

Management Comments

• Paul A. Wagner, Ph.D., Chairman, President, and Chief Executive Officer, expressed appreciation for stockholders' continued support and urged them to vote.
• The Board believes its current leadership structure supports the risk oversight function of the Board.

Industry Context

Proxy statements and annual meetings are standard practice for publicly traded companies, ensuring shareholder participation in key decisions. The proposals outlined are typical for such meetings.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, is generally in line with industry standards for similarly sized biotech companies.
• The use of KPMG LLP as an independent auditor is a common practice among publicly traded companies to ensure financial transparency and compliance.
• The virtual format of the annual meeting aligns with a growing trend towards increased accessibility and reduced costs.

Related Party Transactions

• On July 31, 2023, certain executive officers, senior management, and Board members of the Company participated in a private placement, purchasing approximately $1.16 million of shares of Common Stock at a purchase price of $25.25 per share (as adjusted for the Company's most recent reverse stock split).
• On November 21, 2024, certain executive officers and senior management of the Company participated in a private placement, purchasing approximately $125,000 of shares of Common Stock at a purchase price of $5.552 per share.
• The Company and Dr. Finck entered into a consulting agreement, as more fully described in the section titled Director Compensation.

Stakeholder Impact

• Stockholders have the opportunity to influence the company's direction through voting on key proposals.
• The election of directors will shape the composition of the Board and its oversight of the company.
• The ratification of the auditor ensures financial transparency and accountability.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will hold the Annual Meeting on May 29, 2025.
• The Board will continue to oversee the company's operations and strategic direction.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Auditor Ratification, Corporate Governance, Stockholders, KPMG, Board of Directors, Compensation, Forte Biosciences